Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659656 | 0.86 | ACHE (0.66) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL5659567 | 0.86 | ALDH1A1 (0.71) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL4609842 | 0.85 | CES1 (0.66) | ALDH3A1ALDH1A1ALDH2CHRM5CES1 | |
| SCHEMBL18954793 | 0.84 | ALDH3A1 (0.69) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL16798714 | 0.84 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2CA12CA1 | |
| SCHEMBL30774282 | 0.83 | CES1 (0.67) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL18974316 | 0.83 | CES1 (0.67) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL18954802 | 0.83 | CHRM5 (0.60) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL14740713 | 0.83 | CHRM5 (0.73) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL18954800 | 0.82 | CHRM5 (0.58) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2750508-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Wayne State University (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | ALDH3A1 1858/4885ALDH1A1 2506/4885ALDH2 1751/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | ALDH3A1 1858/4885ALDH1A1 2506/4885ALDH2 1751/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | ALDH3A1 1858/4885ALDH1A1 2506/4885ALDH2 1751/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | ALDH3A1 1858/4885ALDH1A1 2506/4885ALDH2 1751/4885 |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | ALDH3A1 1412/4885ALDH1A1 196/4885ALDH2 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.